Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

89bio, Inc. ETNB NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$22.00
+48.2%

89bio, Inc. (ETNB) is a Biotechnology company in the Healthcare sector, currently trading at $14.84. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ETNB = $22 (+48.2% upside).

Net income is $367M (loss), growing at -70.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $38M against $401M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 13.19 (strong liquidity). Debt-to-assets is 7.8%. Total assets: $479M.

Analyst outlook: 9 / 15 analysts rate ETNB as buy (60%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$22.00
▲ 48.25% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for 89bio, Inc., the average price target is $22.00, with a high forecast of $29.00, and a low forecast of $12.00.
Highest Price Target
$29.00
Average Price Target
$22.00
Lowest Price Target
$12.00

ETNB SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ETNB

✓
VALUE Pass
90/100
ETNB trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $22, implying +48.2% from the current price $15. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ETNB: +0%/yr revenue is, -70.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ETNB: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 13.19 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
ETNB: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 9 / 15 analysts rate ETNB as buy (60%). Analyst consensus target is $22 (+48.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.16-15.06
Volume38.51M
Avg Volume (30D)5.39M
Market Cap$2.2B
Beta (1Y)1.26
Share Statistics
EPS (TTM)-3.51
Shares Outstanding$104.71M
IPO Date2019-11-11
Employees93
CEORohan Palekar
Financial Highlights & Ratios
EBITDA$-384.66M
Net Income$-367.08M
Operating Income$-384.66M
Total Cash$439.96M
Total Debt$37.55M
Net Debt$-88.51M
Total Assets$478.69M
Price / Earnings (P/E)-4.2
Analyst Forecast
1Y Price Target$25.00
Target High$29.00
Target Low$12.00
Upside+68.5%
Rating ConsensusBuy
Analysts Covering15
Buy 60% Hold 40% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS2825591033

Price Chart

Track all markets on TradingView
ETNB
89bio, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
4.16 52WK RANGE 15.06

People Also View

MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 TGTX
TGTX
TG Therapeutics, Inc.
$34.56
+2.28%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 VKTX
VKTX
Viking Therapeutics, Inc.
$35.52
+1.46%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message